Rationale for Anticoagulant Therapy of Pulmonary Fibrosis
نویسندگان
چکیده
منابع مشابه
Anticoagulant Therapy and Idiopathic Pulmonary Fibrosis
1 Nathan RA, Yancey SW, Waitkus-Edwards K, et al. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest 2005; 128:1910–1920 2 Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001; 357:2007–20...
متن کاملAnticoagulant therapy and idiopathic pulmonary fibrosis.
STUDY OBJECTIVE To evaluate the effect of anticoagulant therapy on the survival of patients with idiopathic pulmonary fibrosis (IPF). DESIGN Prospective study. SETTING Five hospitals located in the Miyagi prefecture in Japan, including a university hospital, a Red Cross hospital, two public general hospitals, and a municipal hospital. PATIENTS Fifty-six patients with IPF (mean age, 69.4 y...
متن کاملAnticoagulant Therapy and Idiopathic Pulmonary Fibrosis
1 Nathan RA, Yancey SW, Waitkus-Edwards K, et al. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest 2005; 128:1910–1920 2 Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001; 357:2007–20...
متن کاملThe effect of anticoagulant therapy for idiopathic pulmonary fibrosis in real life practice.
BACKGROUND IPF is a common form of interstitial lung disease for which there is no effective therapy and usually results in death. Two previous contradictory studies showed anticoagulant therapy to be associated with both improved and worsened survival, respectively. OBJECTIVE The objective of this retrospective cohort study was to evaluate the effect of anticoagulant therapy on the survival...
متن کاملThe Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry
Background. The relative rarity and diversity of fibrotic interstitial lung disease (ILD) have made it challenging to study these diseases in single-centre cohorts. Here we describe formation of a multicentre Canadian registry that is needed to describe the outcomes of fibrotic ILD and to enable detailed healthcare utilization analyses that will be the cornerstone for future healthcare planning...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Respiratory and Critical Care Medicine
سال: 2014
ISSN: 1073-449X,1535-4970
DOI: 10.1164/rccm.201305-0845le